Atyr_Logo.png
aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 04, 2018 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
Atyr_Logo.png
aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference
November 21, 2017 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
November 14, 2017 16:05 ET | aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
Atyr_Logo.png
aTyr Pharma Announces Leadership Transition
November 01, 2017 16:05 ET | aTyr Pharma, Inc.
– Dr. John Mendlein Transitions from CEO to Non-Executive Board Member,Dr. Sanjay Shukla Appointed President and CEO – SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE),...